2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2344 Targeting CAR T cell-derived IFNγ to overcome macrophage-mediated immunosuppression and CAR T cell resistance in B cell lymphoma

Allan Pavy, PhD, Nolan Beatty, PhD2, Payal Goala, PhD3, Sae Bom Lee, PhD4, Jianmin Wang5, Meredith L. Stone, PhD6, Marco Davila, MD, PhD7
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
4 Seoul National University, Seoul, Korea, Rep. of South
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Although chimeric antigen receptor (CAR) T cell therapy has improved outcomes in large B cell lymphoma (LBCL), most patients exhibit resistance or relapse. We previously linked non-durable responses to Axicabtagene ciloleucel (axi-cel) to an M2-like macrophage-rich tumor microenvironment (TME). In coculture models, CAR T-derived IFNγ promotes inducible nitric oxide synthase (iNOS) in M2-like immunoregulatory macrophages (imMac) and impairs CAR T cell activity via apoptosis and metabolic rewiring. Inhibition of iNOS or IFNγ restores CAR T cell function in vitro, but it remained unclear how clinically available strategies like blockade of IFNγ or IFNγ deletion in CAR T cells would impact outcomes in vivo. Here, we evaluated strategies targeting IFNγ and CAR T cell efficacy in an immune competent TME and investigated potential persistent mechanisms of immunosuppression. We examined both CAR T cell-intrinsic IFNγ deletion and systemic IFNγ blockade in immunocompetent C57BL/6 mice bearing Eμ-myc tumors (n=8 mice/group). As anticipated, 1928z CAR T cells suppressed tumor growth and improved median survival from 17.5±1 days with control 19dz CAR T cells to undefined (p=0.0076, Mantel-Cox); however, neither IFNγ deficiency nor anti-IFNγ significantly improved CAR T cell efficacy. IFNγ deletion, but not IFNγ blockade, reduced macrophage iNOS expression from 24% to 8% (p=0.0012, n=4 mice/group, ordinary one-way ANOVA with Tukey’s test). The failure of IFNγ-/- CAR T cells to improve efficacy despite reduced iNOS+ macrophages suggests that IFNγ may have an anti-tumor role or that other immunosuppressive mechanisms remain in the TME.

First, we considered that IFNγ deletion hindered anti-tumor iNOS on M1-like macrophages. IFNγ-/- CAR T cells drastically decreased iNOS expression in imMac (1% vs 74% in imMac exposed to WT CAR), but not M1-like macrophages (82%; p<0.0001, unpaired t test, n=3 coculture replicates). Blocking IFNγ in coculture produced the same pattern, reducing iNOS in imMac by 20% while leaving M1-like macrophages unchanged (p<0.0001 and p=0.9656, respectively, ordinary one-way ANOVA with Tukey’s test, n=3 coculture replicates). iNOS was dispensable for CAR T-cell expansion and cytotoxicity in the presence of M1-macrophages, rather than necessary for anti-tumor function (n=4 coculture replicates). In conclusion, inhibiting IFNγ secretion by CAR T cells does not dampen CAR anti-tumor activity with iNOS+ M1-like macrophages.

Second, we investigated additional immunosuppressive mechanisms in the TME that may limit efficacy by performing single-cell RNA sequencing (scRNAseq) on cocultures of WT or IFNγ-/- CAR T cells with unpolarized macrophages or imMac. Unsupervised clustering analysis confirmed a major imMac cluster in WT CAR T cell coculture that was characterized by increased Nos2/iNOS, as expected, as well as inhibitory checkpoint ligands Cd274 (PD-L1) and Pdcd1lg2 (PD-L2). At the protein level, WT CAR T cell coculture increased imMac PD-L1 expression from 46% to 89% (p<0.0001, n=3 coculture replicates, n=3 independent experiments), which was not reduced by IFNγ deletion, in contrast to iNOS. Therefore, persistent co-expression of immunosuppressive markers in imMac likely drives a profoundly immunosuppressive TME that promotes CAR T therapy failure. scRNAseq analysis also revealed a major imMac cluster that persisted in coculture with IFNγ-/- CAR T cells that was enriched for genes including Trem2, Csf1r, Arg1, and Tgfb1 (adj. p < 0.0001), consistent with suppressive, lipid- and matrix-remodeling features. Functionally, TREM2 promotes lipid uptake, phagocytosis, macrophage persistence, and an immunosuppressive transcriptional state that limits T-cell responses. In solid tumors, TREM2+ macrophages are commonly associated with poor prognosis, T-cell dysfunction, T-cell exclusion, and therapeutic resistance. Gene set enrichment analysis of this TREM2+ cluster also showed strong enrichment of cell-cycle pathways, indicating a proliferative macrophage subset. Together, these data suggest that IFNγ/iNOS signaling is only one component of a broader macrophage-mediated suppressive network. Our work supports exploring IFNγ-targeted interventions, coupled with patient stratification using transcriptomic, genomic, or inflammatory biomarkers to overcome immunosuppression in the TME.

Allan Pavy, PhD: No relevant conflicts of interest to declare.